Allow Me To Introduce You To
- Posted by Frank Zorrilla
- on January 13th, 2015
It seems like the Biotech sector has become the can’t miss sector of 2015, everything I read and hear is bullish, and probably rightfully so. Many of the big cap biotechs make a ton of money and have fantastic pipelines. However, stocks/sectors go up AND down not up OR down, and it seems to me that many believe that biotech is now a one way street, up. The biotech sector without a doubt has reached the acceptance stage after 5 years and a 360% move (NBI-X), and its probably getting to the euphoric stage.
Allow me to introduce you to $BIS.
ProShares UltraShort Nasdaq Biotechnology seeks daily investment results, before fees and expenses, that correspond to two times the inverse (-2x) of the daily performance of the NASDAQ Biotechnology Index®.
This will come in handy to those who believe that sectors go up and down not up or down, and will like to possibly take advantage of a POSSIBLE post euphoric (blow off) move.
Zor Capital LLC is a New York based investment management firm, founded in 2011. Our goal is superior performance, with preservation of capital as our number one priority. Zor Capital manages separate accounts (both taxable and retirement) for accredited investors and institutions. This structure gives clients access to a hedge fund like strategy while maintaining 100% control of their accounts. Managed Assets
The information in this blog post represents my own opinions and does not contain a recommendation for any particular security or investment. I or my affiliates may hold positions or other interests in securities mentioned in the Blog, please see my Disclaimer page for my full disclaimer.
blog comments powered by Disqus
Frank Zorrilla is the founder and chief investment officer of Zor Capital LLC.He began his Wall Street career 10 days after his 20th birthday when he became a Series 7 licensed stock broker. More »
Nothing beats verified actual performance
Sign up for ZorTrades FREE updates.
Additional Articles and Updates